Keine Internetverbindung – die gespeicherte Version der Seite wird angezeigt.

10x Genomics, Inc…

USUSD
← Zum Screener
US:TXGLSE:0A88

10x Genomics, Inc. (LSE:0A88) — Biotechnology: Laboratory Analytical Instruments. Anzahl der Börsen, an denen die Aktien des Unternehmens gehandelt werden: 2. Auf dieser Seite: Kurs und Chart, Dividenden, größte Aktionäre und Entwicklung der Aktienanzahl.

Über das Unternehmen

Website
10xgenomics.com
Sektor
Industrials · Biotechnology: Laboratory Analytical Instruments
Hauptsitz
Pleasanton, United States
CEO
Serge Saxonov
Mitarbeiter
1 178
Gegründet
2012
Ausstehende Aktien
120.21 Mio.
Streubesitz
118.19 Mio.
Marktkapitalisierung
11.53 Mrd. USD
Insider
1.46%
Institutionelle Anleger
120.2%
Branche (SIC)
Laboratory Analytical Instruments
Rechtsform
XTIQ
ISIN
US88025U1097
LEI
5493003Z6741WNLG7H43
P/E
Verlust
FCF
121 Mio. USD
Schulden
0 USD
Nettoliquidität
Gewinne und FCF – für die 12 Monate bis 30.06.2026 (aktueller Bericht des Unternehmens).
NAV
6.87 USD · P/NAV 12.9
Bilanzdatum30.06.2026
Aktiva1.03 Mrd. USD
− Verbindlichkeiten205 Mio. USD
= NAV (Eigenkapital der Unternehmensaktionäre)826 Mio. USD
− Goodwill6.92 Mio. USD
− Immaterielle Vermögenswerte61.2 Mio. USD
= Materielle NAV757 Mio. USD
Aktien120 212 296
NAV pro Aktie6.87 USD
Greifbarer NAV pro Aktie6.30 USD
Aktienkurs (0A88)88.3100 USD
P/NAV12.86
NAV-Verlauf
BilanzdatumNAVNAV pro Aktie
30.06.2026826 Mio. USD6.87 USD
31.03.2026814 Mio. USD6.77 USD
31.12.2025796 Mio. USD6.24 USD
30.09.2025785 Mio. USD6.53 USD
30.06.2025773 Mio. USD6.43 USD
31.03.2025707 Mio. USD5.88 USD
31.12.2024710 Mio. USD5.81 USD
30.09.2024723 Mio. USD6.01 USD
Beschreibung

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Anzeige

Börsen und Ticker

BörseTickerWährungPreisTyp
US USA StocksTXG primärUSD71.55 +2.58%Stammaktie
LSE London Stock Exchange0A88 IOBUSD88.31 +0.00%Stammaktie

Kurs über 3 Monate

Tag mit Kursanstieg Tag mit KursrückgangTag mit der Maus berühren / antippen — Eröffnungs-, Schluss-, Höchst- und Tiefstkurs

Größte Anteilseigner

InhaberAnteilAktienBerichtsdatum
FMR, LLC14.67%17.63 Mio.2026-06-30
Blackrock Inc.8.99%10.8 Mio.2026-06-30
ARK Investment Managemen…8.32%10 Mio.2026-06-30
Vanguard Portfolio Manag…5.81%6.98 Mio.2026-06-30
Quantinno Capital Manage…4.55%5.47 Mio.2026-06-30
Vanguard Capital Managem…4.23%5.08 Mio.2026-06-30
Price (T.Rowe) Associate…3.78%4.54 Mio.2026-06-30
Sumitomo Mitsui Trust Gr…3.49%4.19 Mio.2026-06-30
Amova Asset Management A…3.49%4.19 Mio.2026-06-30
VANGUARD INDEX FUNDS-Van…2.94%3.53 Mio.2026-06-30
Morgan Stanley2.79%3.35 Mio.2026-06-30
iShares Trust-iShares Ru…2.53%3.04 Mio.2026-07-31
ARK ETF Trust-ARK Genomi…2.53%3.04 Mio.2026-08-31
ARK ETF Trust-ARK Innova…2.5%3.01 Mio.2026-08-31
VANGUARD INDEX FUNDS-Van…2.12%2.55 Mio.2026-06-30
Fidelity Select PORT.s-S…1.66%2 Mio.2026-07-31
Fidelity Rutland Square…1.37%1.65 Mio.2026-07-31
Fidelity Select Portfoli…1.34%1.61 Mio.2026-07-31
VANGUARD INDEX FUNDS-Van…1.22%1.47 Mio.2026-06-30
T. Rowe Price New Horizo…1.21%1.46 Mio.2026-06-30
SAXONOV SERGE WILSON (Ch…≈1.11%1.34 Mio.2026-09-22
HINDSON BENJAMIN J (Pres…≈0.41%488 1822026-08-24
STUELPNAGEL JOHN R (Dire…≈0.27%328 4362026-09-03
TAICH ADAM (Chief Financ…≈0.26%316 3442026-09-09
MATEO ALAN V. (Director)≈0.07%85 8772026-06-04
KOSARAJU SRIDHAR (Direct…≈0.06%68 2782026-06-04
POPOVITS KIMBERLY J (Dir…≈0.03%37 4452026-06-04
TEICHMANN SARAH A. (Dire…≈0.02%28 0582026-08-14
SULIMAN SHEHNAAZ (Direct…≈0.02%23 7922026-09-22